Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer™
VANCOUVER, December 31, 2019 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for...